### **Overview** ANG Lifesciences India Limited is a publicly listed, pure-play pharmaceutical formulation company incorporated in 2006 and headquartered in Baddi, Himachal Pradesh, India. The company specializes in manufacturing and marketing a diversified portfolio of high-quality finished pharmaceutical formulations, with a strong focus on both domestic and international markets. It operates state-of-the-art, WHO-GMP and ISO-certified manufacturing facilities located in Baddi, ensuring compliance with global quality standards. --- ### **Core Business & Product Portfolio** - **Therapeutic Focus Areas**: Antibiotics, antivirals, antimalarials, antiulcer drugs, carbapenems, corticosteroids, penicillins (with beta-lactamase inhibitors), pain management, anti-inflammatories, and critical care medicines. - **Dosage Forms**: Dry powder injections, liquid injections, tablets, capsules, soft gelatin capsules, syrups (liquid and dry), ointments, lotions, and pre-filled syringes. - **Key Segments**: Non-Beta Lactam, Beta Lactam, Cephalosporin, and Carbapenem products. - **Portfolio Size**: Offers over **1,000 formulations**, minimizing product concentration risk and enabling diversified revenue streams. --- ### **Manufacturing & Infrastructure** - **Facilities**: Operates **seven WHO-GMP-compliant manufacturing units** in Baddi, Himachal Pradesh. These include: - Flagship facility and newly integrated units from acquisitions (ex-Ind-Swift Units 3–4, renamed Unit 5 & 6). - Dedicated **penicillin formulation plant** (ex-Star Biotech). - **Unit V** with a new pre-filled syringes (PFS) line commissioned for enhanced injectable offerings. - A **menthol manufacturing plant** with 10,000 metric tons per annum (TPA) capacity—contributing 20% to global menthol production. - **Capacity (as of 2025)**: - 3 billion tablets/year - 90 million liquid injection ampoules - 48 million liquid injection vials - 120 million dry syrups - 960 million soft gelatin capsules - 24 million ointments and 4 million lotions - 140 million dry powder injection vials (post-IPO expansion) - All manufacturing is done in-house, ensuring quality control and compliance with global pharmacopeia standards. --- ### **Strategic Growth & Expansion** ANG Lifesciences has executed a robust growth strategy through **acquisitions, backward integration, and technological upgrades**: #### **Key Acquisitions & Integration** - **Star Biotech Pvt Ltd (2019)**: Acquired to establish a dedicated penicillin formulation unit; expanded and commissioned by FY22. - **MBP Pharmaceuticals (Jan 2021)**: Enabled expansion into beta-lactam oral solids (tablets, capsules, dry syrups). - **Ind-Swift Ltd’s Units 3 & 4 (2021, ₹60 crore)**: Significantly increased capacity; now operate as **Unit 5 and Unit 6** of ANG. - **Mansa Printers & Publishers Ltd (Apr 2021)**: Strategic **backward integration** into pharmaceutical packaging to reduce costs (packaging = 15–20% of product cost) and secure supply chain. #### **Greenfield & Brownfield Projects** - **Pre-filled Syringes (PFS) Line**: Commissioned in Unit V to strengthen injectable pipeline. - **Greenfield Facility**: Planned on surplus land for **anti-cancer drugs and nutraceuticals** to support future growth. - **Surgical Unit**: Future plan for land acquired from Jot Saroop Knits (currently used as warehouse). --- ### **Global & Domestic Footprint** - **Markets**: Serves **India, Africa, Gulf countries, Latin America, and Southeast Asia**. - **Export Strategy**: Targeting **250+ product registrations** in semi- and regulated markets (Latin America, Africa, SEA) by FY23–24. Aimed for **₹500 crore in export revenue by FY23–24**. - **Sales & Distribution**: Pan-India presence with strong outreach to **government institutions, third-party manufacturing (contract), and direct marketing channels**. --- ### **Backward Integration & Sustainability Goals** - **API & Intermediate Focus**: Long-term strategy to **reduce dependence on Chinese imports** by entering API and derivative manufacturing. - **Process Optimization**: Investment in advanced technologies to reduce solvent usage, by-product formation, pollution, and overall production costs. - **Sustainability**: Emphasis on **green manufacturing and reduced environmental impact** through continuous process improvements. --- ### **Subsidiary Transactions (as of Sep 2025)** - **Mansa Prints and Publishers Limited** (subsidiary): - Loan provided: ₹125.00 lakh - Interest income earned: ₹33.61 lakh - Land acquired: ₹381.35 lakh - Goods purchased: ₹241.26 lakh - Revenue from sales to subsidiary: ₹202.47 lakh *Indicates active intercompany operations supporting packaging integration and cost optimization.*